Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results

Diabetes, Obesity and Metabolism

Volumn 9, Issue 4, 2007, Pages 506-511

  Ristic, Smiliana ^a   Collober Maugeais, ^a   Cressier, F ^a   Tang, P ^a   Pecher, E ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Gliclazide; HbA1c; Metformin; Nateglinide; Type 2 diabetes mellitus

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC PATIENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN RESPONSE; INTERVERTEBRAL DISK HERNIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MEAL; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSTATE ADENOMA; RHINOPHARYNGITIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; THORAX PAIN; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; UPPER RESPIRATORY TRACT INFECTION; WEIGHT GAIN;

EID: 34347392693     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00632.x     Document Type: Article

References (10)

1. James DE. MUNC-ing around with insulin action. J Clin Invest 2005; 115: 219-221.
2. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
3. Goodarzi MO, Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005; 7: 654-665.
4. UK Prospective Diabetes Study Group. UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. Diabetes Care 1998; 21: 87-92.
5. Ristic S, Collober-Maugeais C, Pecher E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with type 2 diabetes inadequately controlled on maximum doses of metformin alone. Diabet Med 2006; 23: 757-762.
6. Maher LJ, Edwards G, Lee CE et al. Long-term combination therapy with pioglitazone plus metformin for type 2 diabetes: A randomized comparative study with gliclazide plus metformin. Diabetologia 2003; 46 (Suppl. 2): A28.
7. UK Prospective Diabetes Study Group. UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed insulin-dependent diabetes followed for three years. Br Med J 1995; 310: 83-88.
8. UK Prospective Diabetes Study Group. UKPDS 33: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
9. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 2006; 29 (Suppl. 1): S4-S42.
10. Mari A, Gastaldelli A., Foley JE et al. Beta-cell function in mild type 2 diabetic patients: Effects of 6-month glucose lowering with nateglinide. Diabetes Care 2005; 28: 1132-1138.